---
categories: 
- Database
- Release
date: 2023-02-02
title: Database release
---
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.

Added entries:
- (FDA) _ERBB2_ copy number amplifications and sensitivity to trastuzumab in combination with tucatinib in colorectal cancer.
- (FDA) _ESR1_ somatic variants and sensitivity to elacestrant in breast cancer.